Spatiotemporal‐Controlled NIR‐II Immune Agonist Sensitizes Cancer Immunotherapy
Shuai Guo,Dongsheng Tang,Mengjie Zhang,Haiyin Yang,Tian Zhang,Bo Hu,Chun Xu,Yuhua Weng,Kun Shang,Yuanyu Huang
DOI: https://doi.org/10.1002/adma.202400228
IF: 29.4
2024-03-15
Advanced Materials
Abstract:The integration of nanomedicine and immunotherapy has presented a promising opportunity for treatment of cancer and diverse diseases. However, achieving spatiotemporal controllable immunotherapy with excellent efficacy and safety performances remains a significant challenge. This study develops a biodegradable near‐infrared‐II (NIR‐II) photothermal response polymer nanoparticle (PTEQ) system. This platform exhibits intrinsic immunostimulatory properties while concurrently delivering siRNA targeting the programmed death‐ligand 1 gene (siPD‐L1), leveraging enhanced immune responses and immune checkpoint blockade (ICB) for safe and effective cancer therapy. In the CT26 tumor‐bearing mouse model, PTEQ, as an immune stimulant, significantly boosted the infiltration of CD4+ and CD8+ T cells within the tumor microenvironment (TME). The PTEQ/siPD‐L1+laser group not only initiated NIR‐II photothermal therapy but also promoted the activation and infiltration of T cells, M1 macrophage polarization, and maturation of dendritic cells (DCs) in the TME, resulting in the complete elimination of tumors in 7/10 cases a 100% survival rate. In another in vivo vaccine experiments, all tumors on the right side were completely eliminated in the PTEQ/siPD‐L1+laser group, reaching a 100% tumor eradication rate. These findings underscore the potential of this strategy to overcome the limitations of current immunotherapeutic limitations and achieve immune therapy normalization. This article is protected by copyright. All rights reserved
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology